C7A.029

Clinical Causes: Genetic mutations that affect neuroendocrine cell behavior Family history of neuroendocrine tumors or other related cancers Chronic inflammatory conditions of the colon, such as Crohn's disease or ulcerative colitis Exposure to certain carcinogens, although this is less common Age-related changes, with higher incidence typically seen in adults over 50

Key Symptoms: Persistent abdominal pain or discomfort Changes in bowel habits, such as diarrhea or constipation Unexplained weight loss Abdominal swelling or mass sensation Bleeding from the rectum or blood in stools Fatigue and weakness due to anemia or overall health decline Occasional hormone-related symptoms if the tumor secretes active substances (e.g., flushing, diarrhea)

Diagnosis Path: Detecting a malignant carcinoid tumor in the large intestine typically involves a combination of clinical evaluation and diagnostic tests. Patients may undergo procedures such as colonoscopy, where doctors can visualize the inside of the colon and take tissue samples for biopsy. Imaging studies like CT scans, MRI, or somatostatin receptor scintigraphy can help determine the tumor's location and assess if it has spread. Laboratory tests measuring specific markers may also assist in diagnosis and monitoring. Ultimately, histopathological examination of the biopsy confirms the neuroendocrine nature and malignancy of the tumor.

Treatment Protocols: Management of malignant carcinoid tumors in the large intestine may include surgical removal of the tumor or affected colon segment to eliminate cancerous tissue. Additional treatments, such as targeted therapies, chemotherapy, or somatostatin analogs, might be recommended to control tumor growth or manage hormone-related symptoms. Regular follow-up care involves imaging and laboratory tests to monitor for recurrence or metastasis. In some cases, multidisciplinary care teams collaborate to personalize treatment plans based on tumor size, location, stage, and patient health status.